Court Date for Biogen and Elan Set for Sept. 3
This article was originally published in The Pink Sheet Daily
Executive Summary
The partners, who are litigating over Tysabri, face off earlier than expected.
You may also be interested in...
A Safety Net That May Not Be So Safe: Elan Sues Biogen Over J&J Deal
Elan's new deal with J&J over its key Alzheimer's assets runs into a brick wall: Biogen.
Painting a Rosy Picture, Beleaguered Elan Seeks To Leave Its Troubles Behind
Elan reveals a hidden sweetener in its J&J deal, which will enable it to bid for the half of Tysabri it doesn't already own in the event Biogen is bought.
J&J And Elan Strike A Deal On Key Alzheimer's Disease Assets
Six months after announcing it was looking at strategic alternatives, Elan's beleaguered management has found a way to address its challenges: It announced July 2 that it is selling its Alzheimer's immunotherapy program (AIP), which includes the high-profile Alzheimer's disease drug bapineuzumab and all related assets, to Johnson & Johnson for what essentially amounts to $500 million in the near-term and a commitment from J&J to buy an 18.4 percent stake in Elan for $1 billion